INmune Bio (INMB) Set to Announce Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, May 9th.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.47) EPS for the quarter. INmune Bio had a negative net margin of 19,360.00% and a negative return on equity of 64.11%. The firm had revenue of $0.03 million for the quarter.

INmune Bio Stock Performance

Shares of INmune Bio stock opened at $10.90 on Wednesday. The stock has a market capitalization of $198.38 million, a P/E ratio of -6.69 and a beta of 1.92. INmune Bio has a 52-week low of $6.50 and a 52-week high of $14.74. The stock’s 50-day simple moving average is $11.14 and its 200 day simple moving average is $10.65.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.